

AUTHOR INDEX FOR VOLUME 17

- Abbruzzese, J. L.** See Hubbard, K. P.
- Abe, M.** See Shibamoto, Y.
- Abe, R.**
- Tsuchiya A.; Koie H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Kikuchi, K.: A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan, 103
- Abo, S.** See Abe, R.
- Adams, M.** See Janjan, N. A.
- Adelstein, D. J.**
- Rice, T. W.; Boyce G. A.; Sivak, M. V.; Van Kirk, M. A.; Kirby, T. J.; van Stolk, R. U.; Bukowski, R. M.: Adenocarcinoma of the esophagus and gastroesophageal junction: Clinical and pathologic assessment of response to induction chemotherapy, 14
 - Saxton, J. P.; Van Kirk, M. A.; Wood, B. G.; Eliachar, I.; Tucker, H. M.; Lavertu, P.: Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer, 369
- Ahmann, F.** See Marshall, M. E.
- Ahn, M. J.**
- Lee, J. S.; Lee, K. H.; Suh, C.; Choi, S. S.; Kim, S-H. B.: A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy, 150
- Airoma, G.** See Gridelli, C.
- Akman, S. A.** See Margolin, K. A.
- Alberts, D. S.** See Malviya, V. K.
- Alevizakos, N.** See Pectasides, D.
- Allan, S. E.** See Costa, M. A.
- Allred, C.** See Khansur, T.
- Alonso, K.**
- Medenica, R.: Immunomodulation in the treatment of malignant disorders, 41
 - Pontiggia, P.; Sabato, A.; Calvi, G.; Cuppone Curto, F.; de Bartolomei, E.; Nardi, C.; Cereda, P.: Systemic hyperthermia in the treatment of HIV-related disseminated Kaposi's sarcoma: Long-term follow-up of patients treated with low-flow extracorporeal perfusion hyperthermia, 353
- Anderson, S.** See Mamounas, E. P.
- Andrade, C. A. V.** See Costa, M. A.
- Aramendia, J. M.** See Martínez-Monge, R.
- Arcangeli, G.** See Gridelli, C.
- Arcicasa, M.**
- Roncadin, M.; Bortolus, R.; Bassignano, G.; Boz, G.; Franchin, G.; De Paoli, A.; Trovò, M. G.: Results of three consecutive combined treatments for malignant gliomas: Ten-year experience at a single institution, 437
- Ardalan, B.** See Feun, L. G.
- Ardizzoni, A.**
- Pennucci, M. C.; Castagneto, B.; Mariani, G. L.; Cinquegrana, A.; Magri, D.; Verna, A.; Salvati, F.; Rosso, R.: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma, 80
- Aristu, J. J.** See Martínez-Monge, R.
- Asbury, R. F.** See Hsieh, R-K.
- Blessing, J. A.; Soper, J. T.: A gynecologic oncology group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix, 125
 - Cnaan, A.; Johnson, L.; Harris, J.; Zaentz, S. D.; Haller, D. G.: An eastern cooperative oncology group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer, 166
- Asimakopoulos, G.** See Pectasides, D.
- Athanassiou, A.** See Pectasides, D.
- Atzpodien, J.** See Schomburg, A.
- Azab, M.** See Kattan, J.
- Azinovic, I.** See Martínez-Monge, R.
- Bacoyiannis, C.** See Tsavaris, N.
- Bafaloukos, D.** See Pectasides, D.
- Bailey, A.** See Robert, F.
- Baker, L. H.** See Blair, S. C.
- Baker, T. R.** See Hempling, R. E.
- Bakshi, S.** See Hempling, R. E.
- Baltzer, L.** See Tyson, L. B.
- Bar-Ziv, J.** See Drakos, P.
- Barbounis, V.** See Pectasides, D.
- Barnes, W. A.** See Burnett, A. F.
- Barré, D. M.** See Mendenhall, N. P.; Molot, R. J.
- Barrios, C.**
- Castresana, J. S.; Kreicbergs, A.: Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with *c-myc* oncogene amplification, 273
- Barter, J. F.** See Burnett, A. F.
- Bass, D.** See Omura, G. A.
- Bassignano, G.** See Arcicasa, M.
- Bear, H. D.** See Mamounas, E. P.
- Benasso, M.** See Merlano, M.
- Benedetto, P.** See Feun, L. G.
- Benson, A. B., III** See Buzdar, A. U.
- Berry, W.** See Buzdar, A. U.
- Bertolone, S.**, 475
- Bertuccelli, M.** See Brunetti, I.
- Betsis, D.** See Fountzilas, G.
- Bianco, A. R.** See Gridelli, C.; Perrone, F.
- Biete, A.** See Grau, J-J.
- Bigler, R. D.** See Vonderheid, E. C.
- Blair, S. C.**
- Zalupski, M. M.; Baker, L. H.: Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas, 480
- Blanch, J. L.** See Grau, J-J.
- Blend, M. J.** See Vijayakumar, V.
- Blengio, F.** See Merlano, M.
- Blessing, J. A.** See Asbury, R. F.
- Blumenreich, M. S.**
- Sheth, S. P.; Miller C. L.; Farnsley, E. S.; Kelliham, M. J.; Joseph, U. G.; Hamm, J. T.; Seeger, J.; Robinson, L. H.; Hagan, P. C.; Sullivan, D. M.; Woodcock, T. M.: Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer, 163
- Blumenstein, B.** See Marshall, M. E.
- Bonomi, P.**
- Finkelstein, D.; Chang, A.: Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An eastern cooperative oncology group study, 215
- Bornstein, R.** See Mamounas, E. P.
- Boros, L.** See Hsieh, R-K.
- Bortolus, R.** See Arcicasa, M.
- Bourazanis, J.** See Pectasides, D.

AUTHOR INDEX FOR VOLUME 17

- Abbruzzese, J. L.** See Hubbard, K. P.
- Abe, M.** See Shibamoto, Y.
- Abe, R.**
- Tsuchiya A.; Koie H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Kikuchi, K.: A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan, 103
- Abo, S.** See Abe, R.
- Adams, M.** See Janjan, N. A.
- Adelstein, D. J.**
- Rice, T. W.; Boyce G. A.; Sivak, M. V.; Van Kirk, M. A.; Kirby, T. J.; van Stolk, R. U.; Bukowski, R. M.: Adenocarcinoma of the esophagus and gastroesophageal junction: Clinical and pathologic assessment of response to induction chemotherapy, 14
 - Saxton, J. P.; Van Kirk, M. A.; Wood, B. G.; Eliachar, I.; Tucker, H. M.; Lavertu, P.: Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer, 369
- Ahmann, F.** See Marshall, M. E.
- Ahn, M. J.**
- Lee, J. S.; Lee, K. H.; Suh, C.; Choi, S. S.; Kim, S-H. B.: A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy, 150
- Airoma, G.** See Gridelli, C.
- Akman, S. A.** See Margolin, K. A.
- Alberts, D. S.** See Malviya, V. K.
- Alevizakos, N.** See Pectasides, D.
- Allan, S. E.** See Costa, M. A.
- Allred, C.** See Khansur, T.
- Alonso, K.**
- Medenica, R.: Immunomodulation in the treatment of malignant disorders, 41
 - Pontiggia, P.; Sabato, A.; Calvi, G.; Cuppone Curto, F.; de Bartolomei, E.; Nardi, C.; Cereda, P.: Systemic hyperthermia in the treatment of HIV-related disseminated Kaposi's sarcoma: Long-term follow-up of patients treated with low-flow extracorporeal perfusion hyperthermia, 353
- Anderson, S.** See Mamounas, E. P.
- Andrade, C. A. V.** See Costa, M. A.
- Aramendia, J. M.** See Martínez-Monge, R.
- Arcangeli, G.** See Gridelli, C.
- Arcicasa, M.**
- Roncadin, M.; Bortolus, R.; Bassignano, G.; Boz, G.; Franchin, G.; De Paoli, A.; Trovò, M. G.: Results of three consecutive combined treatments for malignant gliomas: Ten-year experience at a single institution, 437
- Ardalan, B.** See Feun, L. G.
- Ardizzoni, A.**
- Pennucci, M. C.; Castagneto, B.; Mariani, G. L.; Cinquegrana, A.; Magri, D.; Verna, A.; Salvati, F.; Rosso, R.: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma, 80
- Aristu, J. J.** See Martínez-Monge, R.
- Asbury, R. F.** See Hsieh, R-K.
- Blessing, J. A.; Soper, J. T.: A gynecologic oncology group phase II study of amonafide (NSC #308847) in squamous cell carcinoma of the cervix, 125
 - Cnaan, A.; Johnson, L.; Harris, J.; Zaentz, S. D.; Haller, D. G.: An eastern cooperative oncology group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer, 166
- Asimakopoulos, G.** See Pectasides, D.
- Athanassiou, A.** See Pectasides, D.
- Atzpodien, J.** See Schomburg, A.
- Azab, M.** See Kattan, J.
- Azinovic, I.** See Martínez-Monge, R.
- Bacoyiannis, C.** See Tsavaris, N.
- Bafaloukos, D.** See Pectasides, D.
- Bailey, A.** See Robert, F.
- Baker, L. H.** See Blair, S. C.
- Baker, T. R.** See Hempling, R. E.
- Bakshi, S.** See Hempling, R. E.
- Baltzer, L.** See Tyson, L. B.
- Bar-Ziv, J.** See Drakos, P.
- Barbounis, V.** See Pectasides, D.
- Barnes, W. A.** See Burnett, A. F.
- Barré, D. M.** See Mendenhall, N. P.; Molot, R. J.
- Barrios, C.**
- Castresana, J. S.; Kreicbergs, A.: Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification, 273
- Barter, J. F.** See Burnett, A. F.
- Bass, D.** See Omura, G. A.
- Bassignano, G.** See Arcicasa, M.
- Bear, H. D.** See Mamounas, E. P.
- Benasso, M.** See Merlano, M.
- Benedetto, P.** See Feun, L. G.
- Benson, A. B., III** See Buzdar, A. U.
- Berry, W.** See Buzdar, A. U.
- Bertolone, S.**, 475
- Bertuccelli, M.** See Brunetti, I.
- Betsis, D.** See Fountzilas, G.
- Bianco, A. R.** See Gridelli, C.; Perrone, F.
- Biete, A.** See Grau, J-J.
- Bigler, R. D.** See Vonderheid, E. C.
- Blair, S. C.**
- Zalupski, M. M.; Baker, L. H.: Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas, 480
- Blanch, J. L.** See Grau, J-J.
- Blend, M. J.** See Vijayakumar, V.
- Blengio, F.** See Merlano, M.
- Blessing, J. A.** See Asbury, R. F.
- Blumenreich, M. S.**
- Sheth, S. P.; Miller C. L.; Farnsley, E. S.; Kelliham, M. J.; Joseph, U. G.; Hamm, J. T.; Seeger, J.; Robinson, L. H.; Hagan, P. C.; Sullivan, D. M.; Woodcock, T. M.: Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer, 163
- Blumenstein, B.** See Marshall, M. E.
- Bonomi, P.**
- Finkelstein, D.; Chang, A.: Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An eastern cooperative oncology group study, 215
- Bornstein, R.** See Mamounas, E. P.
- Boros, L.** See Hsieh, R-K.
- Bortolus, R.** See Arcicasa, M.
- Bourazanis, J.** See Pectasides, D.

- Boyce G. A. *See* Adelstein, D. J.
 Boyce, M. *See* Conroy, T.
 Boz, G. *See* Arcicasa, M.
 Brada, M.
 —Book review, 181
 Brady, L. W. *See* Micaily, B.
 Brancaccio, L. *See* Gridelli, C.
 Brandon, A. H. *See* Wolfson, A. H.
 Braylan, R. C. *See* Molot, R. J.
 Broder, L. E.
 —Sridhar, K. S.; Selawry, O. S.; Charyulu, K. N.; Rao, R. K.; Saldana, M. J.; Donnelly, E. J.; Raub, W. A., Jr.: A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification, 527
 Brunetti, I.
 —Falcone, A.; Bertuccelli, M.; Cianci, C.; Ricci, S.; Conte, P. F.: Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon: A phase I-II study in metastatic colorectal cancer patients, 210
 Bruzzi, P. *See* Chiara, S.
 Bruzzone, M. *See* Chiara, S.
 Buatti, J. M.
 —Harari, P. M.; Leigh, B. R.; Cassady, J. R.: Radiation-induced angiosarcoma of the breast: Case report and review of the literature, 444
 Buccellato, C. *See* Gebbia, V.
 Buckner, J. C. *See* Call, T. G.
 Bufill, J. A.
 —Grace, W. R.; Neff, R.: Intra-arterial chemotherapy for palliation of fungating breast cancer: A case report and review of the literature, 118
 Bukowski, R. M. *See* Adelstein, D. J.
 Burnett, A. F.
 —Barter, J. F.; Potkul, R. K.; Jarvis, T.; Barnes, W. A.: Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer, 490
 Burris, H. A. *See* Eckardt, J. R.
 Burton, G. *See* Cubeddu, L. X.
 Butker, E. *See* Smith, R. G.
 Butler, D.
 —Jose, B.; Summe, R.; Paris, K.; Bertolone, S.; Patel, C. C.; Spanos, W.; Lindberg, R.: Pediatric astrocytomas: The Louisville experience: 1978–1988, 475
 Buzaid, A. C. *See* Murren, J. R.
 —Sandler, A. B.; Hayden, C. L.; Scinto, J.; Poo, W.-J.; Clark, M. B.; Hotchkiss, S.: Neuron-specific enolase as a tumor marker in metastatic melanoma, 430
 Buzdar, A. U.
 —Esparza, L.; Natale, R.; Cody, R.; Calzone, K.; Benson, A. B., III; Sheehan, T.; Berry, W.: Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine: A placebo-controlled study, 417
 Call, T. G.
 —Creagan, E. T.; Frytak, S.; Buckner, J. C.; van Haelst-Pisani, C.; Homburger, H. A.; Katzmann, J. A.: Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease, 344
 Calvi, G. *See* Alonso, K.
 Calzone, K. *See* Buzdar, A. U.
 Campbell, L. *See* Eckardt, J. R.
 Campora, E.
 —Giudici, S.; Merlini, L.; Rubagotti, A.; Rosso, R.: Ondansetron and dexamethasone versus standard combination antiemetic therapy: A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses, 522
 Cantor, A. B. *See* Mendenhall, N. P.
 Cañadell, J.
 —Book review, 181
 Cappelaere, P. *See* Conroy, T.
 Carlomagno, C. *See* Perrone, F.
 Carnino, F. *See* Chiara, S.
 Carriço, M. K. *See* Costa, M. A.
 Casaretti, R. *See* Gridelli, C.
 Cassady, J. R. *See* Buatti, J. M.
 Castagneto, B. *See* Ardizzoni, A.
 Castresana, J. S. *See* Barrios, C.
 Castro, V. *See* Grau, J.-J.
 Catane, R. *See* Drakos, P.
 Cavallari, M. *See* Merlano, M.
 Cereda, P. *See* Alonso, K.
 Champlin, R. E. *See* Seymour, J. F.
 Chang, A. Y. C. *See* Bonomi, P.; Hsieh, R.-K.
 Charalambidis, G. *See* Tsavaris, N.
 Charyulu, K. N. *See* Broder, L. E.
 Chauvergne, J. *See* Conroy, T.
 Checcaglini, F. *See* Darwish, S.
 Chen, S.-C. *See* Yamada, A. H.
 Chen, S. *See* Robert, F.
 Chen, Y. *See* Murren, J. R.
 Chevallier B. *See* Conroy, T.
 Chiara, S.
 —Bruzzone, M.; Merlini, L.; Bruzzi, P.; Rosso, R.; Franzone, P.; Orsatti, M.; Vitale, V.; Foglia, G.; Odicino, F.; Ragni, N.; Rugiati, S.; Conte, P.: Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma, 294
 —Conte, P.F.; Franzone, P.; Orsatti, M.; Bruzzone, M.; Rubagotti, A.; Odicino, F.; Rugiati, S.; Carnino, F.; Rosso R.; Ragni, N.: High-risk early-stage ovarian cancer: Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy, 72
 Choi, S. S. *See* Ahn, M. J.
 Cianci, C. *See* Brunetti, I.
 Cinquegrana, A. *See* Ardizzoni, A.
 Ciociola, A. A. *See* Cubeddu, L. X.
 Cipolla, C. *See* Gebbia, V.
 Clark, M. B. *See* Buzaid, A. C.
 Clark, R. *See* Mamounas, E. P.
 Clark, R. A. *See* Tyson, L. B.
 Clendennin, N. J. *See* Feun, L. G.
 Cnaan, A. *See* Asbury, R. F.
 Cobb, P. *See* Eckardt, J. R.
 Cody, R. *See* Buzdar, A. U.
 Cohen, A. M. *See* Minsky, B. D.
 Cohen, E. *See* Janjan, N. A.
 Cohen, P. R. *See* Morris, L. F.
 Collier, M. *See* Feun, L. G.
 Comande, S. *See* Gebbia, V.
 Comella, G. *See* Gridelli, C.
 Conroy, T.
 —Cappelaere, P.; Fabbro, M.; Fauser, A. A.; Splinter, T. A. W.; Spielmann, M.; Schneider M.; Chevallier B.; Goupil, A.; Chauvergne, J.; Fargeot, P.; Prévot, G.; O'Grady, P.; Green, D.; Hardenberg, J.; Boyce, M.: Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT₃ antagonist, in cancer patients treated with cisplatin, 97
 Conte, P. *See* Chiara, S.
 Conte, P. F. *See* Brunetti, I.
 Conte, P.F. *See* Chiara, S.

- Conti, J. A.
—Kemeny, N.; Klimstra, D.; Minsky, B.; Rusch, V.: Colon carcinoma metastatic to the trachea: Report of a case and a review of the literature, 227
- Costa, M. A.
—Rabinowits, M.; Froimitchuk, M. J.; Olivatto, L. O.; Allan, S. E.; Gil, R. A.; Andrade, C. A. V.; Martino, J. L.; Dobbin, J. A.; Carriço, M. K.; de Castro, O.; Spector, N.; Nucci, M.; Pulcheri, W.; Oliveira, H. P.; Morais, J. C. O.: Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas: The experience in Brazil, 323
- Craig, J. B. See Malviya, V. K.; Marshall, M. E.
- Crawford, E. D. See Marshall, M. E.
- Creagan, E. T. See Call, T. G.
- Crinò, L. See Darwish, S.
- Cruz, J. J. See Fonseca, E.
- Cubeddu, L. X.
—Pendergrass, K.; Ryan, T.; York, M.; Burton, G.; Meshad, M.; Galvin, D.; Ciociola, A. A.: Efficacy of oral ondansetron, a selective antagonist of 5-HT₃ receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies, 137
- Culine, S. See Kattan, J.
- Cuppone Curto, F. See Alonso, K.
- Curcio, C. See Gridelli, C.
- Curto, G. See Gebbia, V.
- D'Aprile, M. See Gridelli, C.
- Darwish, S.
—Minotti, V.; Crinò, L.; Rossetti, R.; Maranzano, E.; Checchaglini, F.; Fiaschini, P.; Mercati, U.; Penza, O.; Vitali, R.; Davis, S.; Latini, P.; Tonato, M.: Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer, 64
- Davis, L. W. See Smith, R. G.
- Davis, S. See Darwish, S.
- de Bartolomei, E. See Alonso, K.
- de Castro, O. See Costa, M. A.
- De Laurentiis, M. See Perrone, F.
- De Paoli, A. See Arcicasa, M.
- De Placido, S. See Gridelli, C.; Perrone, F.
- De Salles, A. F. See Selch, M. T.
- de Souza, P.
—Friedlander, M.; Wilde, C.; Kirsten, F.; Ryan, M.:
Hypersensitivity reactions to etoposide: A report of three cases and review of the literature, 387
- Del Mastro, L. See Perrone, F.
- Del Prete, S. A. See Murren, J. R.
- DeLaney, T. F. See Johnstone, P. A. S.
- Dimitriadis, A. See Fountzilias, G.
- Dimitriadis, M. See Pectasides, D.
- Dobbin, J. A. See Costa, M. A.
- Dodd, L. G. See Morris, L. F.
- Donnelly, E. J. See Broder, L. E.
- Doroshov, J. H. See Margolin, K. A.
- Drakos, P.
—Bar-Ziv, J.; Catane, R.: Tumor lysis syndrome in nonhematologic malignancies: Report of a case and review of the literature, 502
- Droz J-P. See Kattan, J.
- Droz, J-P. See Kattan, J.
- Durand, M. See Kattan, J.
- Durivage, H. J. See Murren, J. R.
- Eckardt, J. R.
—Campbell, L.; Burris, H. A.; Weiss, G. R.; Rodriguez, G. I.; Fields, S. M.; Thurman, A. M.; Peacock, N. W.; Cobb, P.; Rothenberg, M. L.; Ross, M. E.; Von Hoff, D. D.: A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon, 498
- Economides, N. See Pectasides, D.
- Eguchi, K. See Kojima, A.; Shinkai, T.
- Eisenberger, M. See Marshall, M. E.
- Eliachar, I. See Adelstein, D. J.
- Elias, A. D.
—Skarin, A. T.; Gonin, R.; Oliynyk, P.; Stomper, P. C.; O'Hara, C.; Socinski, M. A.; Sheldon, T.; Maggs, P.; Frei, E., III: Neoadjuvant treatment of stage IIIA non-small cell lung cancer: Long-term results, 26
- Elias, D. See Kattan, J.
- Enker, W. E. See Minsky, B. D.
- Esparza, L. See Buzdar, A. U.
- Etapé, J. See Grau, J-J.
- Evans, W. K. See Stewart, D. J.
- Fabbro, M. See Conroy, T.
- Falcone, A. See Brunetti, I.
- Fanning, J.
—Hilgers, R. D.; Hutson, E.: Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer, 335
- Fargeot, P. See Conroy, T.
- Farnsley, E. S. See Blumenreich, M. S.
- Fausser, A. A. See Conroy, T.
- Fenner, M. See Schomburg, A.
- Ferrante, G. See Gridelli, C.
- Feun, L. G. See Wolfson, A. H.
- Reddy, K. R.; Yrizarry, J. M.; Savaraj, N.; Guerra, J. J., Jr.; Purser, R. K.; Waldman, S.; Levi, J. U.; Moffatt, F.; Morrell, L.; Livingstone, A. S.; Ardalán, B.; Benedetto, P.: A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer, 405
- Savaraj, N.; Benedetto, P.; Waldman, S.; Collier, M.; Clendennin, N. J.: Oral pirtrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy?, 448
- Savaraj, N.; Hung, S.; Reddy, R.; Jeffers, L.; Benedetto, P.; Livingstone, A. S.; Ardalán, B.; Levi, J. U.; Parker, T.; Schiff, E. R.: A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma, 393
- Fiaschini, P. See Darwish, S.
- Fields, S. M. See Eckardt, J. R.
- Finkelstein, D. See Bonomi, P.
- Fisher, B. See Mamounas, E. P.
- Foglia, G. See Chiara, S.
- Foley, D. See Janjan, N. A.
- Fonseca, E.
—Cruz, J. J.; Gomez, A.; Sanchez, P.; Martin, G.; Santos, P.; Muñoz, A.; Nieto, A.: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer, 6
- Fountzilias, G.
—Betsis, D.; Nikopoulos, A.; Zaramboukas, T.; Dimitriadis, A.; Tourkantonis, A.: Extragenital choriocarcinoma in a patient with Down syndrome, 452
- Franchin, G. See Arcicasa, M.
- Franzone, P. See Chiara, S.
- Frei, E., III See Elias, A. D.
- Friedlander, M. See de Souza, P.
- Froimitchuk, M. J. See Costa, M. A.
- Frytak, S. See Call, T. G.
- Fu, A. L.
—Greven, K. M.; Maruyama, Y.: Radiation osteitis and insufficiency fractures after pelvic irradiation for gynecologic malignancies, 248
- Fusco, V. See Guerrieri, P.

- Galinsky, D. L.**
—Sharma, M.; Hartsell, W. F.; Griem, K. L.; Murthy, A.: Primary radiation therapy to T1 and T2 breast cancer following conservative surgery: Which patients should be boosted?, 60
- Galvin, D.** See Cubeddu, L. X.
- Garcia, D. M.** See Halverson, K. J.
- Gebbia, N.** See Gebbia, V.
- Gebbia, V.** See Gridelli, C.
- Valenza, R.; Testa, A.; Cipolla, C.; Latteri, M.; Curto, G.; Comande, S.; Buccellato, C.; Gebbia, N.: Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas, 485
- Gentile, M.** See Gridelli, C.
- Giampaglia, F.** See Gridelli, C.
- Gil, R. A.** See Costa, M. A.
- Gilani, S. S. H.** See Hempling, R. E.
- Gill, P.** See Keung, Y. K.
- Giudici, S.** See Campora, E.
- Glaspj, J.** See Tse, N.
- Glass, A. G.** See Mamounas, E. P.
- Gogou, L.** See Pectasides, D.
- Gomez, A.** See Fonseca, E.
- Gomez, E. G.** See Vogel, C. L.
- Gonin, R.** See Elias, A. D.
- Goupil, A.** See Conroy, T.
- Grace, W. R.** See Bufill, J. A.
- Gramer, E. M.** See Howard, L. M.
- Grau, J.-J.:**
—Palombo, H.; Estapé, J.; Mañé, J.-M.; Blanch, J. L.; Vilalta, A.; Castro, V.; Biete, A.: Carboplatin plus fluorouracil as a palliative treatment in locally advanced cancer of the oral cavity and lip, 134
- Gravina, A.** See Perrone, F.
- Green, D.** See Conroy, T.
- Green, S.** See Margolin, K. A.
- Greenberg, A. S.** See Vonderheid, E. C.
- Greven, K. M.** See Fu, A. L.
- Gridelli, C.** See Perrone, F.
- Ianniello, G. P.; Maiorino, A.; Curcio, C.; D'Aprile, M.; Brancaccio, L.; Palmeri, S.; Gentile, M.; Comella, G.; Pedicini, T.; Airoma, G.; Veltri, E.; Gebbia, V.; Russo, A.; Casaretti, R.; Giampaglia, F.; Ferrante, G.; Rausa, L.; Iacobelli, S.; Arcangeli, G.; De Placido, S.; Bianco, A. R.: Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer, 160
- Griem, K. L.** See Galinsky, D. L.
- Grosh, W.** See Murphy, B. R.
- Groschen, S.** See Yamada, A. H.
- Guerra, J. J., Jr.** See Feun, L. G.
- Guerrieri, P.**
—Modoni, S.; Parisi, S.; Fusco, V.; Oriolo, V.; Rendina, G.; Palciani-Vettori, P. G.: Bone formation markers and pain palliation in bone metastases treated with strontium-89, 77
- Hagan, P. C.** See Blumenreich, M. S.
- Hait, W. N.** See Murren, J. R.
- Haller, D. G.** See Asbury, R. F.
- Halverson, K. J.**
—Taylor, M. E.; Perez, C. A.; Garcia, D. M.; Myerson, R.; Philpott, G.; Levy, J.; Simpson, J. R.; Tucker, G.; Rush, C.: Management of the axilla in patients with breast cancers one centimeter or smaller, 461
- Hamm, J. T.** See Blumenreich, M. S.; Mamounas, E. P.
- Harari, P. M.** See Buatti, J. M.
- Hardenberg, J.** See Conroy, T.
- Harris, J.** See Asbury, R. F.
- Hartsell, W. F.** See Galinsky, D. L.
- Thomas, C. R., Jr.; Murthy, A. K.; Taylor, S. G., IV; Haselow, R. E.: Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385), 338
- Haselow, R. E.** See Hartsell, W. F.
- Hawkins, R.** See Tse, N.
- Hayden, C. L.** See Buzaid, A. C.
- Hempling, R. E.**
—Piver, M. S.; Baker, T. R.; Bakshi, S.; Gilani, S. S. H.: Immunoscintigraphy using ¹¹¹InCyt103 prior to second look laparotomy in ovarian cancer: A pilot study, 331
- Herberman, R. B.**
—Letter to the editor, 382
- Herreros, J.** See Martínez-Monge, R.
- Hesketh, P. J.**
Oral ondansetron: A useful addition to the supportive care armamentarium?, 147
- Hilgers, R. D.** See Fanning, J.
- Hill, B. T.**
—Price, L. A.: Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate, 1
- Hiremth, V.** See Howard, L. M.
- Hoh, C.** See Tse, N.
- Homburger, H. A.** See Call, T. G.
- Hotchkiss, S.** See Buzaid, A. C.
- Houdek, P. V.** See Wolfson, A. H.
- Howard, L. M.**
—Kasimis, B. S.; Gramer, E. M.; Ruddy, P.; Hiremath, V.; Pokorney, E. S.: A phase II trial of alternating chemotherapy in patients with inoperable non-small cell lung cancer, 83
- Hsieh, R.-K.**
—Chang, A. Y. C.; Boros, L.; Asbury, R.: Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer, 509
- Hubbard, K. P.**
—Roehm, J. O. F., Jr.; Abbruzzese, J. L.: The bird's nest filter: An alternative to long-term oral anticoagulation in patients with advanced malignancies, 115
- Hughes, L. L.** See Smith, R. G.
- Hung, S.** See Feun, L. G.
- Hutchins, L.** See Margolin, K. A.
- Hutson, E.** See Fanning, J.
- Iacobelli, S.** See Gridelli, C.
- Ianniello, G. P.** See Gridelli, C.
- Ishihara, H.** See Kigawa, J.
- Itamochi, H.** See Kigawa, J.
- Itoh, M.** See Matsue, K.
- Janjan, N. A.**
—Cohen, E.; Adams, M.; Stewart, E.; Foley, D.; Varma, R.: Radiation tolerance of the transplanted liver: A histopathologic study in three cases, 129
- Jarvis, T.** See Burnett, A. F.
- Jeffers, L.** See Feun, L. G.
- Johnson, L.** See Asbury, R. F.
- Johnstone, P. A. S.**
—Mican, J. A. M.; Metcalfe, D. D.; DeLaney, T. F.: Radiotherapy of refractory bone pain due to systemic mast cell disease, 328
- Jose, B.** 475
- Joseph, U. G.** See Blumenreich, M. S.
- Kajanti, M.**
—Pyrhonen, S.: Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system: A phase II study, 223
- Kajita, M.** See Saito, H.

- Kanamori, Y. *See* Kigawa, J.
 Karabelis, A. *See* Tsavaris, N.
 Kasimis, B. S. *See* Howard, L. M.
 Kattan, J.
 —Durand, M.; Droz, J.-P.; Mahjoubi, M.; Marino, J.-P.; Azab, M.: Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule, 242
 —Spatz, A.; Culine, S.; Terrier-Lacombe, M.-J.; Elias, D.; Droz, J.-P.: Hepatocellular carcinoma during hormonotherapy for prostatic cancer, 390
 Katzmann, J. A. *See* Call, T. G.
 Keating, M. J. *See* Seymour, J. F.
 Kelliham, M. J. *See* Blumenreich, M. S.
 Kemeny, N. *See* Conti, J. A.
 Keung, Y. K.
 —Lau, S.; Gill, P.: Extramedullary plasmacytoma of the heart presenting as cardiac emergency: Review of literature, 427
 Khansur, T.
 —Allred, C.; Tavassoli, M.: 5-fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors, 506
 Khoroshkov, V. S.
 —Onosovsky, K. K.; Klenov, G. I.; Zink, S.: Moscow hospital-based proton therapy facility design, 109
 Khouri, I. F. *See* Seymour, J. F.
 Kigawa, J.
 —Minagawa, Y.; Itamochi, H.; Kanamori, Y.; Ishihara, H.; Terakawa, N.: Retroperitoneal lymphadenectomy, including the para-aortic nodes in patients with stage III ovarian cancer, 230
 Kikuchi, K. *See* Abe, R.
 Kim, S.-H. B. *See* Ahn, M. J.
 Kirby, T. J. *See* Adelstein, D. J.
 Kirchner, H. *See* Schomburg, A.
 Kirsten, F. *See* de Souza, P.
 Klenov, G. I. *See* Khoroshkov, V. S.
 Klimstra, D. *See* Conti, J. A.
 Koie H. *See* Abe, R.
 Kojima, A. *See* Shinkai, T.
 Körfer, A. *See* Schomburg, A.
 Kojima, A.
 —Shinkai, T.; Soejima, Y.; Okamoto, H.; Eguchi, K.; Sasaki, Y.; Tamura, T.; Oshita, F.; Ohe, Y.; Saijo, N.: A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients, 400
 Kokubo, T. *See* Matsue, K.
 Kosmidis, P. *See* Tsavaris, N.
 Koutsouba, P. *See* Pectasides, D.
 Kreicbergs, A. *See* Barrios, C.
 Kris, M. G. *See* Tyson, L. B.
 Kumar, S. R. *See* Kusumakumari, P.
 Kusumakumari, P.
 —Kumar, S. R.; Rajasekharan, G.: Unusual clinical course of chronic myelogenous leukemia: A case report, 19
 Landry, J. C. *See* Smith, R. G.
 Landy, H. *See* Wolfson, A. H.
 Langholz, B. M. *See* Petrovich, Z.
 Latini, P. *See* Darwish, S.
 Latteri, M. *See* Gebbia, V.
 Lau, S. *See* Keung, Y. K.
 Lauwers, G. *See* Minsky, B. D.
 Lavertu, P. *See* Adelstein, D. J.
 Lawson, D. H. *See* Smith, R. G.
 Lee, J. S. *See* Ahn, M. J.
 Lee, K. H. *See* Ahn, M. J.
 Leigh, B. R. *See* Buatti, J. M.
 Leong, L. A. *See* Margolin, K. A.
 Levi, J. U. *See* Feun, L. G.
 Levy, J. *See* Halverson, K. J.
 Lieskovsky, G. *See* Yamada, A. H.
 Liggett, P. E. *See* Petrovich, Z.
 Lindberg, R., 475
 Lingareddy, V. *See* Mohiuddin, M.
 Liu, P. Y. *See* Malviya, V. K.
 Livingstone, A. S. *See* Feun, L. G.
 Loehrer, P. J. *See* Murphy, B. R.
 Logan, D. *See* Stewart, D. J.
 Lokich, J.
 Metastatic adamantinoma of bone to lung: A case report of the natural history and the use of chemotherapy and radiation therapy, 157
 Lopez-Hänninen, E. *See* Schomburg, A.
 Lynch, J. W., Jr. *See* Mendenhall, N. P.
 Lynn, M. *See* Smith, R. G.
 McCormick, R. E. *See* Weinerman, B. H.
 Maggs, P. *See* Elias, A. D.
 Magri, D. *See* Ardizzone, A.
 Mahjoubi, M. *See* Kattan, J.
 Maiorino, A. *See* Gridelli, C.
 Malviya, V. K.
 —Liu, P. Y.; O'Toole, R.; Alberts, D. S.; Surwit, E.; Rosenoff, S.; Ward, J. H.; Yu, A.; O'Sullivan J.; Craig, J. B.: Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma: A southwest oncology group study, 37
 Mamounas, E. P.
 —Anderson, S.; Wickerham, D. L.; Clark, R.; Stoller, R.; Hamm, J. T.; Stewart, J. A.; Bear, H. D.; Glass, A. G.; Bornstein, R.; Fisher, B.: The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination: An NSABP pilot study in patients with metastatic or high-risk primary breast cancer, 374
 Mañé, J.-M. *See* Grau, J.-J.
 Maranzano, E. *See* Darwish, S.
 Margolin, K. A.
 —Green, S.; Osborne, K.; Doroshow, J. H.; Akman, S. A.; Leong, L. A.; Morgan, R. J.; Raschko, J. W.; Somlo, G.; Hutchins, L.; Upchurch, C.: Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer, 175
 Mariani, G. L. *See* Ardizzone, A.
 Marino, J.-P. *See* Kattan, J.
 Markoe, A. M. *See* Wolfson, A. H.
 Marks, G. *See* Mohiuddin, M.
 Marshall, M. E.
 —Blumenstein, B.; Crawford, E. D.; Thompson, I. M.; Craig, J. B.; Eisenberger, M.; Ahmann, F.: Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate: A southwest oncology group study, 514
 Martin, G. *See* Fonseca, E.
 Martínez-Monge, R.
 —Herreros, J.; Aristu, J. J.; Aramendía, J. M.; Azinovic, I.: Combined treatment in superior sulcus tumors, 317
 Martino, J. L. *See* Costa, M. A.
 Maruyama, Y. *See* Fu, A. L.
 Matsue, K.
 —Itoh, M.; Tsukuda, K.; Miyazaki, K.; Kokubo, T.: Successful treatment of cytophagic histiocytic panniculitis with modified CHOP-E: Cyclophosphamide, adriamycin, vincristine, predonisona, and etoposide, 470
 McDonnell, J. M. *See* Petrovich, Z.

- Medenica, R. *See* Alonso, K.
- Mendenhall, N. P. *See* Molot, R. J.
- Cantor, A. B.; Barré, D. M.; Lynch, J. W., Jr.; Million, R. R.: The role of prognostic factors in treatment selection for early-stage Hodgkin's disease, 189
- Menzel, T. *See* Schomburg, A.
- Mercati, U. *See* Darwish, S.
- Merlano, M.
- Benasso, M.; Cavallari, M.; Blengio, F.; Sguotti, C.; Rosso, M.; Rosso, R.: Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck: A phase I study, 494
- Merlini, L. *See* Campora, E.; Chiara, S.
- Meshad, M. *See* Cubeddu, L. X.
- Metcalfe, D. D. *See* Johnstone, P. A. S.
- Micaily, B. *See* Vonderheid, E. C.
- Miyamoto, C.; Valicenti, R. K.; Brady, L. W.: Intracavitary brachytherapy for squamous cell carcinoma of the esophagus, 170
- Mican, J. A. M. *See* Johnstone, P. A. S.
- Miller, C. L. *See* Blumenreich, M. S.
- Million, R. R. *See* Mendenhall, N. P.
- Minagawa, Y. *See* Kigawa, J.
- Minotti, V. *See* Darwish, S.
- Minsky, B. *See* Conti, J. A.
- Minsky, B. D.
- Enker, W. E.; Cohen, A. M.; Lauwers, G.: Local excision and postoperative radiation therapy for rectal cancer, 411
- Miyamoto, C. *See* Micaily, B.
- Miyazaki, K. *See* Matsue, K.
- Modoni, S. *See* Guerrieri, P.
- Moffatt, F. *See* Feun, L. G.
- Mohiuddin, M.
- Lingareddy, V.; Marks, G.: Long-term results of "selective sandwich" adjunctive radiotherapy for cancer of the rectum, 264
- Molot, R. J.
- Mendenhall, N. P.; Barré, D. M.; Braylan, R. C.: The clinical relevance of L26, a B-cell-specific antibody, in Hodgkin's disease, 185
- Molthrop, D. *See* Robert, F.
- Morais, J. C. O. *See* Costa, M. A.
- Morgan, R. J. *See* Margolin, K. A.
- Mori, S. *See* Abe, R.
- Moroni, M. *See* Porta, C.
- Morrell, L. *See* Feun, L. G.
- Morris, L. F.
- Cohen, P. R.; Dodd, L. G.: Nongenital granuloma inguinale in an oncology patient, 456
- Mueller, C. B.
- Breast cancer: Reporting results with inflationary arithmetic, 86
- Muñoz, A. *See* Fonseca, E.
- Murphy, B. R.
- Rynard, S. M.; Pennington, K. L.; Grosh, W.; Loehrer, P. J.: A phase II trial of vinblastine plus dipyrindamole in advanced renal cell carcinoma: A Hoosier oncology group study, 10
- Murphy, G. J. *See* Murren, J. R.
- Murren, J. R.
- Durivage, H. J.; Rosenberg, A. H.; Chen, Y.; Del Prete, S. A.; Murphy, G. J.; Buzaid, A. C.; Hait, W. N.: Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer: Limited activity of an aggressive chemotherapy regimen, 239
- Murthy, A. *See* Galinsky, D. L.
- Murthy, A. K. *See* Hartsell, W. F.
- Myerson, R. *See* Halverson, K. J.
- Mylonakis, N. *See* Tsavaris, N.
- Nardi, C. *See* Alonso, K.
- Nastasi, G. *See* Porta, C.
- Natale, R. *See* Buzdar, A. U.
- Neff, R. *See* Bufill, J. A.
- Neukum, S. J. *See* Vonderheid, E. C.
- Nieto, A. *See* Fonseca, E.
- Niimi, T. *See* Saito, H.
- Nikopoulos, A. *See* Fountzilas, G.
- Nucci, M. *See* Costa, M. A.
- O'Grady, P. *See* Conroy, T.
- O'Hara, C. *See* Elias, A. D.
- O'Sullivan, J. *See* Malviya, V. K.
- O'Toole, R. *See* Malviya, V. K.
- Odicino, F. *See* Chiara, S.
- Ohe, Y. *See* Kojima, A.; Shinkai, T.
- Okamoto, H. *See* Kojima, A.
- Olivatto, L. O. *See* Costa, M. A.
- Oliveira, H. P. *See* Costa, M. A.
- Oliynyk, P. *See* Elias, A. D.
- Omura, G. A.
- Bass, D.: Prognostic factor analysis of central nervous system relapse in adult acute lymphoblastic leukemia: A southeastern cancer study group report, 93
- Perri, R. T.; Peterson, B.; Schiffer, C. A.: Carboplatin in previously treated multiple myeloma: A cancer and leukemia group B phase II trial, 196
- Ono, K. *See* Abe, R.
- Onosovsky, K. K. *See* Khoroshkov, V. S.
- Oriolo, V. *See* Guerrieri, P.
- Orsatti, M. *See* Chiara, S.
- Osborne, K. *See* Margolin, K. A.
- Oshita, F. *See* Kojima, A.
- Pagliarulo, C. *See* Perrone, F.
- Pagou, M. *See* Tsavaris, N.
- Paleani-Vettori, P. G. *See* Guerrieri, P.
- Palmer, D. *See* Petrovich, Z.
- Palmeri, S. *See* Gridelli, C.
- Palombo, H. *See* Grau, J.-J.
- Paris, K., 475
- Parisi, S. *See* Guerrieri, P.
- Parker, R. G. *See* Selch, M. T.
- Parker, T. *See* Feun, L. G.
- Patel, C. C., 475
- Peacock, N. W. *See* Eckardt, J. R.
- Pectasides, D.
- Alevizakos, N.; Bafaloukos, D.; Tzonou, A.; Asimakopoulos, G.; Varthalitis, I.; Dimitriadis, M.; Athanassiou, A.: Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma, 55
- Barbounis, V.; Sintila, A.; Varthalitis, I.; Dimitriadis, M.; Athanassiou, A.: Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy, 68
- Economides, N.; Bourazanis, J.; Pozadzizou, P.; Gogou, L.; Koutsoubas, P.; Athanassiou, A.: Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer, 307
- Pedicini, T. *See* Gridelli, C.
- Pellicer, A.
- Book review, 182
- Pendergrass, K. *See* Cubeddu, L. X.
- Pennington, K. L. *See* Murphy, B. R.
- Pennucci, M. C. *See* Ardizzone, A.
- Penza, O. *See* Darwish, S.
- Perez, C. A. *See* Halverson, K. J.
- Perri, R. T. *See* Omura, G. A.

- Perrone, F.
—De Placido, S.; Carlomagno, C.; Gravina, A.; De Laurentiis, M.; Del Mastro, L.; Gridelli, C.; Pagliarulo, C.; Bianco, A. R.: Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients: A phase II study, 218
- Peterson, B. *See* Omura, G. A.
- Petrovich, Z. *See* Yamada, A. H.
- McDonnell, J. M.; Palmer, D.; Langholz, B. M.; Liggett, P. E.: Histopathologic changes following irradiation for uveal tract melanoma, 298
- Phelps, M. *See* Tse, N.
- Philpott, G. *See* Halverson, K. J.
- Pisters, K. M. W. *See* Tyson, L. B.
- Piver, M. S. *See* Hempling, R. E.
- Pokorney, E. S. *See* Howard, L. M.
- Poliwoda, H. *See* Schomburg, A.
- Pontiggia, P. *See* Alonso, K.
- Poo, W.-J. *See* Buzaid, A. C.
- Porta, C.
—Moroni, M.; Nastasi, G.: Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis, 246
- Potkul, R. K. *See* Burnett, A. F.
- Powell, R. W. *See* Smith, R. G.
- Pozadzizou, P. *See* Pectasides, D.
- Prévot, G. *See* Conroy, T.
- Price, L. A. *See* Hill, B. T.
- Pulcheri, W. *See* Costa, M. A.
- Purser, R. K. *See* Feun, L. G.
- Pyrhönen, S. *See* Kajanti, M.
- Quadri, S. F. *See* Vijayakumar, V.
- Rabinowits, M. *See* Costa, M. A.
- Ragni, N. *See* Chiara, S.
- Rajasekharan, G. *See* Kusumakumari, P.
- Rao, R. K. *See* Broder, L. E.
- Raschko, J. W. *See* Margolin, K. A.
- Raub, W. A., Jr. *See* Broder, L. E.
- Rausa, L. *See* Gridelli, C.
- Reddy, K. R. *See* Feun, L. G.
- Reddy, R. *See* Feun, L. G.
- Rendina, G. *See* Guerrieri, P.
- Ricci, S. *See* Brunetti, I.
- Rice, T. W. *See* Adelstein, D. J.
- Rigas, J. R. *See* Tyson, L. B.
- Robert, F.
—Wheeler, R. H.; Molthrop, D.; Bailey, A.; Chen, S.: Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer, 383
- Robinson, L. H. *See* Blumenreich, M. S.
- Rodriguez, G. I. *See* Eckardt, J. R.
- Rodriguez, M. *See* Wolfson, A. H.
- Roehm, J. O. F., Jr. *See* Hubbard, K. P.
- Roncadin, M. *See* Arcicasa, M.
- Rosenberg, A. H. *See* Murren, J. R.
- Rosenoff, S. *See* Malviya, V. K.
- Ross, M. E. *See* Eckardt, J. R.
- Rossetti, R. *See* Darwish, S.
- Rosso R. *See* Chiara, S.
- Rosso, M. *See* Merlano, M.
- Rosso, R. *See* Ardizzoni, A.; Campora, E.; Chiara, S.; Merlano, M.
- Rothenberg, M. L. *See* Eckardt, J. R.
- Rubagotti, A. *See* Campora, E.; Chiara, S.
- Ruddy, P. *See* Howard, L. M.
- Rudolph, P. *See* Schomburg, A.
- Rugiati, S. *See* Chiara, S.
- Rusch, V. *See* Conti, J. A.
- Rush, C. *See* Halverson, K. J.
- Russo, A. *See* Gridelli, C.
- Ryan, M. *See* de Souza, P.
- Ryan, T. *See* Cubeddu, L. X.
- Rynard, S. M. *See* Murphy, B. R.
- Sabato, A. *See* Alonso, K.
- Saijo, N. *See* Kojima, A.; Shinkai, T.
- Saito, H.
—Shimokata, K.; Yamori, S.; Kajita, M.; Niimi, T.: Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis, 422
- Saito, K. *See* Abe, R.
- Saldana, M. J. *See* Broder, L. E.
- Salvati, F. *See* Ardizzoni, A.
- Sanchez, P. *See* Fonseca, E.
- Sandler, A. B. *See* Buzaid, A. C.
- Sano, T. *See* Shinkai, T.
- Santos, P. *See* Fonseca, E.
- Sasaki, Y. *See* Kojima, A.; Shinkai, T.
- Sato, T. *See* Abe, R.
- Savaraj, N. *See* Feun, L. G.
- Saxton, J. P. *See* Adelstein, D. J.
- Schiff, E. R. *See* Feun, L. G.
- Schiffer, C. A. *See* Omura, G. A.
- Schneider M. *See* Conroy, T.
- Schomburg, A.
—Kirchner, H.; Lopez-Hänninen, E.; Menzel, T.; Rudolph, P.; Körfer, A.; Fenner, M.; Poliwoda, H.; Atzpodien, J.: Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon- α : Evidence of a risk-benefit advantage of subcutaneous therapy, 199
- Schwade, J. G. *See* Wolfson, A. H.
- Scinto, J. *See* Buzaid, A. C.
- Seeger, J. *See* Blumenreich, M. S.
- Selawry, O. S. *See* Broder, L. E.
- Selch, M. T.
—Shimizu, K. T.; De Salles, A. F.; Sutton, C.; Parker, R. G.: Primary central nervous system lymphoma: Results at the University of California at Los Angeles and review of the literature, 286
- Seymour, J. F.
—Khouri, I. F.; Champlin, R. E.; Keating, M. J.: Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation: Case report and review, 360
- Sguotti, C. *See* Merlano, M.
- Sharma, M. *See* Galinsky, D. L.
- Sheehan, T. *See* Buzdar, A. U.
- Sheldon, T. *See* Elias, A. D.
- Sheth, S. P. *See* Blumenreich, M. S.
- Shibamoto, Y.
—Yamashita, J.; Takahashi, M.; Abe, M.: Intraoperative radiation therapy for brain tumors with emphasis on retreatment for recurrence following full-dose external beam irradiation, 396
- Shimizu, K. T. *See* Selch, M. T.
- Shimokata, K. *See* Saito, H.
- Shinkai, T. *See* Kojima, A.
- Tamura, T.; Sano, T.; Kojima, A.; Eguchi, K.; Sasaki, Y.; Ohe, Y.; Saijo, N.: In vitro and in vivo cytogenetic effects of recombinant interleukin-2 on human lymphocytes, 50
- Simpson, J. R. *See* Halverson, K. J.
- Sintila, A. *See* Pectasides, D.
- Sivak, M. V. *See* Adelstein, D. J.
- Skarin, A. T. *See* Elias, A. D.
- Skinner, D. G. *See* Yamada, A. H.
- Smith, R. G.
—Landry, J. C.; Wood, W. C.; Styblo, T.; Hughes, L. L.; Lynn,

- M.; York, R. M.; Powell, R. W.; Butker, E.; Lawson, D. H.; Davis, L. W.: Conservative treatment of early-stage breast cancer: The Emory experience, 348
- Snodgrass, S. M. *See* Wolfson, A. H.
- Socinski, M. A. *See* Elias, A. D.
- Soejima, Y. *See* Kojima, A.
- Somlo, G. *See* Margolin, K. A.
- Soper, J. T. *See* Asbury, R. F.
- Spanos, W., 475
- Spatz, A. *See* Kattan, J.
- Spector, N. *See* Costa, M. A.
- Spielmann, M. *See* Conroy, T.
- Splinter, T. A. W. *See* Conroy, T.
- Sridhar, K. S. *See* Broder, L. E.; Wolfson, A. H.
- Stewart, D. J.
- Evans, W. K.; Logan, D.: Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites, 313
- Stewart, E. *See* Janjan, N. A.
- Stewart, J. A. *See* Mamounas, E. P.
- Stoller, R. *See* Mamounas, E. P.
- Stomper, P. C. *See* Elias, A. D.
- Styblo, T. *See* Smith, R. G.
- Suh, C. *See* Ahn, M. J.
- Sullivan, D. M. *See* Blumenreich, M. S.
- Summe, R., 475
- Surwit, E. *See* Malviya, V. K.
- Sutton, C. *See* Selch, M. T.
- Takahashi, M. *See* Shibamoto, Y.
- Tamura, T. *See* Kojima, A.; Shinkai, T.
- Tavassoli, M. *See* Khansur, T.
- Taylor, M. E. *See* Halverson, K. J.
- Taylor, S. G., IV *See* Hartsell, W. F.
- Terakawa, N. *See* Kigawa, J.
- Terrier-Lacombe, M.-J. *See* Kattan, J.
- Testa, A. *See* Gebbia, V.
- Thomas, C. R., Jr. *See* Hartsell, W. F.
- Thompson, I. M. *See* Marshall, M. E.
- Thurman, A. M. *See* Eckardt, J. R.
- Tonato, M. *See* Darwish, S.
- Tourkantonis, A. *See* Fountzilas, G.
- Trovò, M. G. *See* Arcicasa, M.
- Tsavaris, N.
- Charalambidis, G.; Pagou, M.; Karabelis, A.; Mylonakis, N.; Bacoyiannis, C.; Kosmidis, P.: Comparison of ondansetron (GR 38032F) versus ondansetron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy, 516
- Tse, N.
- Hoh, C.; Hawkins, R.; Phelps, M.; Glaspy, J.: Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma, 22
- Tsuchiya, A. *See* Abe, R.
- Tsakamoto, M. *See* Abe, R.
- Tsukuda, K. *See* Matsue, K.
- Tucker, G. *See* Halverson, K. J.
- Tucker, H. M. *See* Adelstein, D. J.
- Tyson, L. B.
- Kris, M. G.; Baltzer, L.; Pisters, K. M. W.; Rigas, J. R.; Clark, R. A.: Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin $\epsilon 100$ mg/m², 269
- Tzonou, A. *See* Pectasides, D.
- Upchurch, C. *See* Margolin, K. A.
- Valenza, R. *See* Gebbia, V.
- Valicenti, R. K. *See* Micaily, B.
- van Haelst-Pisani, C. *See* Call, T. G.
- Van Kirk, M. A. *See* Adelstein, D. J.
- van Stolk, R. U. *See* Adelstein, D. J.
- Varma, R. *See* Janjan, N. A.
- Varthalitis, I. *See* Pectasides, D.
- Veltri, E. *See* Gridelli, C.
- Verna, A. *See* Ardizzoni, A.
- Vijayakumar, S. *See* Vijayakumar, V.
- Vijayakumar, V.
- Vijayakumar, S.; Quadri, S. F.; Blend, M. J.: Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?, 432
- Vilalta, A. *See* Grau, J.-J.
- Vitale, V. *See* Chiara, S.
- Vitali, R. *See* Darwish, S.
- Vogel, C. L.
- Gomez, E. G.: A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer, 45
- Von Hoff, D. D. *See* Eckardt, J. R.
- Vonderheid, E. C.
- Bigler, R. D.; Greenberg, A. S.; Neukum, S. J.; Micaily, B.: Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome, 255
- Waldman, S. *See* Feun, L. G.
- Ward, J. H. *See* Malviya, V. K.
- Weinerman, B. H.
- MacCormick, R. E.: A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population, 467
- Weiss, G. R. *See* Eckardt, J. R.
- Wheeler, R. H. *See* Robert, F.
- Wickerham, D. L. *See* Mamounas, E. P.
- Wilde, C. *See* de Souza, P.
- Wolfson, A. H.
- Snodgrass, S. M.; Schwade, J. G.; Markoe, A. M.; Landy, H.; Feun, L. G.; Sridhar, K. S.; Brandon, A. H.; Rodriguez, M.; Houdek, P. V.: The role of steroids in the management of metastatic carcinoma to the brain: A pilot prospective trial, 234
- Wood, B. G. *See* Adelstein, D. J.
- Wood, W. C. *See* Smith, R. G.
- Woodcock, T. M. *See* Blumenreich, M. S.
- Yamada, A. H.
- Lieskovsky, G.; Petrovich, Z.; Chen, S.-C.; Groshen, S.; Skinner, D. G.: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer, 277
- Yamashita, J. *See* Shibamoto, Y.
- Yamori, S. *See* Saito, H.
- York, M. *See* Cubeddu, L. X.
- York, R. M. *See* Smith, R. G.
- Yrizarry, J. M. *See* Feun, L. G.
- Yu, A. *See* Malviya, V. K.
- Zaentz, S. D. *See* Asbury, R. F.
- Zalupski, M. M. *See* Blair, S. C.
- Zaramboukas, T. *See* Fountzilas, G.
- Zink, S. *See* Khoroshkov, V. S.

SUBJECT INDEX FOR VOLUME 17

- Acivicin, in non-small-cell lung cancer, 215
- Aclacinomycin, in pancreatic cancer, 166
- Adamantinoma, metastases, to lung, 157
- Adjuvant therapy. *See also* Neoadjuvant chemotherapy
 - in breast cancer, 102, 348
 - in malignant melanoma, 55
 - in stage TC prostate cancer, 277
- AIDS. *See* HIV-infected (AIDS) patient
- Allopurinol mouthwash, in 5-fluorouracil-induced stomatitis, 246
- Alprazolam, with ondansetron, antiemetic efficacy of, in cisplatin-containing chemotherapy, 516
- Amonafide
 - in endometrial carcinoma, 37
 - in prostate cancer, 514
 - in squamous cell carcinoma of cervix, 125
- Angiosarcoma, radiation-induced, of breast, 444
- Anthracycline pretreatment, in breast cancer, mitomycin C and mitoxantrone in, 218
- Antibiotic therapy, in febrile neutropenic patients, 400
- Anticoagulation, versus Bird's Nest Filter, 115
- Antiemetic
 - combination regimens, trials of, 150
 - dexamethasone and promethazine regimen, lorazepam enhancement of, 417
 - dolasetron mesylate as, 97
 - metoclopramide as, in cisplatin-induced emesis, 422
 - ondansetron as, 137, 147, 150, 269
 - with alprazolam, in cisplatin-containing chemotherapy, 516
 - with dexamethasone, versus standard combination antiemetic therapy, 522
- Astrocytoma, pediatric, 475
- Axillary dissection, in breast cancer, 461
- Biliary system, extrahepatic, advanced cancer of, combination chemotherapy in, 223
- Bird's Nest Filter, 115
- Bladder cancer, piritrexim in, 448
- Blast crisis, 19
- Bone, adamantinoma, metastases to lung, 157
- Bone pain
 - in mast cell disease, radiotherapy in, 328
 - with metastatic disease, strontium-89 therapy and, 77
- Bone scan, in prostate cancer, 432
- Book review
 - Musculoskeletal Oncology: A Multidisciplinary Approach* (Lewis MM, ed), 181
 - Pediatric Neuro-oncology: Trends in Clinical Research* (Packer RJ et al, eds), 181
 - Research Fraud in the Behavioral and Biomedical Sciences* (Miller DD, Hersen M, eds), 182
- Brachytherapy, intracavitary, in esophageal squamous cell carcinoma, 170
- Brain, metastases to, steroid therapy in, 234
- Brain tumors, intraoperative radiation therapy in, 396
- Breast, radiation-induced angiosarcoma, 444
- Breast cancer
 - adjuvant chemoendocrine therapy in, 102
 - advanced
 - anthracycline-pretreated, mitomycin C and mitoxantrone in, 218
 - 5-fluorouracil and high-dose folinic acid in, 175
 - chemotherapy in
 - high-dose, colony-stimulating factors in, 374
 - intra-arterial, 118
 - cisplatin-resistant, pentoxifylline plus nifedipine in, 313
 - data, presentation of, 86
 - early, conservative treatment of, 348
 - fungating, palliation, 118
 - locally advanced, intra-arterial chemotherapy in, 118
 - metastatic, combination therapy with mitoxantrone, 5-fluorouracil, and leucovorin, 45
 - minimal, axillary lymph node management in, 461
 - neglected, intra-arterial chemotherapy in, 118
 - radiation therapy in, postsurgery, 60
 - results reporting, 86
 - salvage treatment, 218
 - tumor lysis syndrome in, 502
- Cancer and Leukemia Group B Phase II Trial, of carboplatin in multiple myeloma, 196
- Carboplatin
 - with epirubicin and VP-16, in small cell lung cancer, 160
 - with etoposide and ifosfamide
 - in advanced non-small cell lung cancer, 509
 - in second-line treatment for ovarian cancer, 335
 - with flutamide, in oral cavity and lip cancer, 134
 - in previously treated multiple myeloma, 196
- Carcinoembryonic antigen, in cervical cancer monitoring, 307
- Central nervous system
 - astrocytoma, pediatric, 475
 - primary lymphoma of, 286
 - prophylaxis, with adult acute lymphoblastic leukemia, 93
 - relapse, in adult acute lymphoblastic leukemia, 93
- Cervix, cancer of
 - advanced, radiotherapy versus chemoradiotherapy in, 294
 - monitoring, tumor markers in, 307
 - squamous cell, amonafide in, 125
- Chemoembolization, with cisplatin and lipiodol, in liver cancer, 405
- Chemoendocrine therapy, in breast cancer, 102
- Chemotherapy. *See also specific agent*
 - in adamantinoma metastatic to lung, 157
 - adjuvant, in melanoma, 55
 - in advanced (stage IIB-III) cervical cancer, 294
 - alternating non-cross-resistant, in inoperable non-small cell lung cancer, 83
 - in breast cancer, high-dose, colony-stimulating factors in, 374
 - combination
 - in advanced cancer of extrahepatic biliary system, 223
 - in breast cancer, 45
 - in fallopian tube carcinoma, 68
 - in melanoma, 55
 - in small cell lung cancer, 160
 - in cytophagic histiocytic panniculitis, 470
 - induction, in esophageal cancer, 14
 - intra-arterial, palliation of fungating breast cancer, 118
 - in malignant glioma, 437
 - in metastatic non-small cell lung cancer, 239
 - neoadjuvant
 - in head and neck cancer, 6

- in non-small cell lung cancer, 26, 64
 - in oral cavity tumors, 1
 - in superior sulcus tumors, 317
- in non-Hodgkin's lymphoma, 323
- in ovarian cancer, versus radiation therapy, 72
- in previously treated multiple myeloma, 196
- in small cell lung cancer, 527
- in squamous cell head and neck cancer, 369
- tumor lysis syndrome in, in nonhematologic malignancy, 502
- CHOP-E, modified, in cytophagic histiocytic panniculitis, 470
- Choriocarcinoma, extragonadal, and Down syndrome, 452
- Chromosomal abnormalities, 50
- Cilastatin, with imipenem, with or without amikacin, in febrile neutropenic patients, 400
- Cisplatin
 - alternating non-cross-resistant chemotherapy with, in inoperable non-small cell lung cancer, 83
 - with cyclophosphamide, in ovarian cancer, versus radiation therapy, 72
 - with dacarbazine and vindesine, in stage II melanoma, 55
 - emesis induced by
 - dolasetron in, 97
 - ondansetron alone versus ondansetron plus alprazolam in, 516
 - ondansetron plus dexamethasone in, 269
 - with etoposide, in non-small cell lung cancer, 64, 215, 383
 - in fallopian tube carcinoma, 68
 - with 5-fluorouracil, and radiotherapy, in retreatment of regionally recurrent head and neck cancer, 338
 - in head and neck cancer, 6
 - with lipiodol, chemoembolization, in liver cancer, 405
 - in metastatic non-small cell lung cancer, 239
 - resistance, chemotherapy in, 313
- Colon cancer. *See* Colorectal cancer
- Colony-stimulating factors
 - in high-dose chemotherapy, 374
 - intensification of chemotherapy, 494
- Colorectal cancer, metastases
 - combination therapy with with 5-fluorouracil, folinic acid, and alpha-2B-interferon, 210
- DaunoXome in, 498
- levofofinic acid and 5-fluorouracil plus hydroxyurea in, 485
- to trachea, 227
- Combined modality therapy
 - in Hodgkin's disease, 189
 - in malignant glioma, 437
 - in retreatment of regionally recurrent head and neck cancer, 338
- Cyclophosphamide
 - with Adriamycin, vincristine, prednisone, and etoposide (CHOP-E), in cytophagic histiocytic panniculitis, 470
 - with CCNU and methotrexate (CCM), in small cell lung cancer, 527
 - dosage, in doxorubicin-cyclophosphamide regimen, in breast cancer, and colony-stimulating factors, 374
 - emesis induced by, ondansetron in, 137
- Cyproterone acetate, in hormoneotherapy for prostate cancer, hepatocellular carcinoma during, 390
- Cytogenetic effects, of interleukin-2, 50
- Cytophagic histiocytic panniculitis, modified CHOP-E in, 470
- Dacarbazine, with vindesine and cisplatin, in stage II melanoma, 55
- Daunorubicin, liposome-encapsulated (DaunoXome), in metastatic colon cancer, 498
- DaunoXome, in metastatic colon cancer, 498
- Deep venous thrombosis, Bird's Nest Filter use with, 115
- Dexamethasone
 - in brain metastases, 234
 - with ondansetron, antiemetic efficacy of
 - in cisplatin-induced emesis, 269
 - trial of, 150
 - with ondansetron and lorazepam, antiemetic efficacy of, trial of, 150
 - with promethazine, antiemetic efficacy of, lorazepam enhancement of, 417
- Dihydroxyanthracenedione, in pancreatic cancer, 166
- Dipyridamole, with vinblastine, in renal cell carcinoma, 10
- Dolasetron mesylate, antiemetic efficacy of, 97
- Down syndrome, testicular cancer and leukemia in, 452
- Doxorubicin
 - with cyclophosphamide
 - in breast cancer, and colony-stimulating factors, 374
 - emesis induced by, ondansetron in, 137
 - with interferon, in hepatocellular carcinoma, 393
 - in metastatic non-small cell lung cancer, 239
- Eastern Cooperative Oncology Group, phase II study
 - of acivicin versus etoposide-cisplatin in non-small cell lung cancer, 215
 - of single agent chemotherapy for pancreatic cancer, 166
- Ellipticine, 242
- Emesis
 - chemotherapy-induced, dexamethasone with promethazine in, lorazepam enhancement of, 417
 - cisplatin-induced
 - dolasetron in, 97
 - metoclopramide in, 422
 - ondansetron alone versus ondansetron plus alprazolam in, 516
 - ondansetron plus dexamethasone in, 269
 - cyclophosphamide-doxorubicin-induced, ondansetron with dexamethasone in, 522
 - cyclophosphamide-induced, ondansetron in, 137
- Endometrial cancer, amonafide in, 37
- Epirubicin, with sequential methotrexate-5-fluorouracil-leucovorin, in advanced cancer of extrahepatic biliary system, 223
- Esophageal cancer
 - 5-fluorouracil, Adriamycin, and mitomycin C in, 506
 - induction chemotherapy for, 14
 - intracavitary brachytherapy in, 170
- Etoposide (VP-16)
 - with carboplatin and ifosfamide
 - in advanced non-small cell lung cancer, 509
 - in second-line treatment for ovarian cancer, 335
 - with cisplatin, in non-small-cell lung cancer, 215, 383
 - with cisplatin or carboplatin, in adamantinoma metastatic to lung, 157
 - hypersensitivity reactions to, 387
 - with ifosfamide, in soft tissue sarcoma, 480
 - in non-small cell lung cancer, 215
 - continuous oral regimen, 163
 - in pancreatic cancer, 166
- External beam radiotherapy
 - in brain metastases, 234
 - in brain tumors, 396
- Fallopian tube carcinoma, cisplatin in, 68
- Febrile neutropenic patients, antibiotic therapy in, 400
- Fluorine-18, PET imaging, 22
- 5-Fluorouracil
 - with Adriamycin and mitomycin C
 - in esophageal cancer, 506
 - in gastroesophageal junction tumors, 506
 - with folinic acid
 - in advanced breast cancer, 175

- plus hydroxyurea, in metastatic gastrointestinal adenocarcinoma, 485
 - and recombinant alpha-2B-interferon, in metastatic colorectal cancer, 210
- in head and neck cancer, 6
- with leucovorin, in pancreatic cancer, phase II survival study, 467
- in metastatic non-small cell lung cancer, 239
- with mitoxantrone and leucovorin, breast cancer chemotherapy with, 45
- in ovarian cancer, 490
- in sequential methotrexate-5-fluorouracil-leucovorin, with epirubicin, in advanced biliary tract cancer, 223
- stomatitis induced by, allopurinol mouthwash in, 246
- Folinic acid, with 5-fluorouracil
 - in advanced breast cancer, 175
 - plus hydroxyurea, in metastatic gastrointestinal adenocarcinoma, 485
 - and recombinant alpha-2B-interferon, in metastatic colorectal cancer, 210
- Fractures, radiation-induced, of female pelvis, 248
- Florafur, with carboplatin, in oral cavity and lip cancer, 134
- Gastroesophageal junction tumors, 5-fluorouracil, Adriamycin, and mitomycin C in, 506
- Glioma, malignant, combined treatments for, 437
- Glucocorticoids, in brain metastases, 234
- Granulocyte colony-stimulating factor, in high-dose chemotherapy, 374
- Granulocyte-macrophage colony-stimulating factor
 - in chemotherapy, for squamous cell head and neck cancer, 494
 - in high-dose chemotherapy, 374
- Granuloma inguinale, nongenital, 456
- Gynecologic Oncology Group, phase II study of amonafide in squamous cell carcinoma of cervix, 125
- Head and neck cancer. *See also* Oral cavity, tumors
 - cisplatin and 5-fluorouracil in, 6
 - combined therapy in, 369
 - retreatment of, 338
 - squamous cell
 - chemotherapy, granulocyte-macrophage colony-stimulating factor in, 494
 - concurrent radiation therapy and chemotherapy in, 369
- Heart, extramedullary plasmacytoma of, 427
- Hepatocellular carcinoma
 - during hormonotherapy for prostate cancer, 390
 - interferon plus doxorubicin in, 393
 - in transplanted liver, radiation therapy in, 129
- HIV-infected (AIDS) patient, Kaposi's sarcoma in, systemic hyperthermia in, 353
- Hodgkin's disease
 - L26 antibody in, 185
 - prognostic factors, in treatment decisions, 189
 - treatment of, 189
- Hoosier Oncology Group, phase II trial of vinblastine plus dipyrindamole in renal cell carcinoma, 10
- 5-Hydroxytryptamine₃ receptor antagonist, antiemetic efficacy of, 97, 137
- Hypercalcemia, in chronic lymphocytic leukemia, 360
- Hypersensitivity reactions, to etoposide, 387
- Hyperthermia
 - in radiation-induced angiosarcoma, 444
 - systemic, in HIV-related Kaposi's sarcoma, 353
- Ifosfamide
 - with carboplatin and etoposide
 - in advanced non-small cell lung cancer, 509
 - in second-line treatment for ovarian cancer, 335
 - with etoposide, in soft tissue sarcoma, 480
- Imipenem, with cilastatin, with or without amikacin, in febrile neutropenic patients, 400
- Immunoscintigraphy, using ¹¹¹Cyt103, prior to second-look surgery, in ovarian cancer, 331
- Immunomodulation, 41
- Immunotherapy
 - in advanced cancer, phase I trial of levamisole with recombinant interleukin-2, 344
 - risk-benefit analysis of, 199
- Interferon
 - with doxorubicin, in hepatocellular carcinoma, 393
 - immunomodulation with, 41
 - in malignant mesothelioma, 80
- Interferon- α
 - recombinant (interferon- α -2B)
 - with doxorubicin, in hepatocellular carcinoma, 393
 - and extracorporeal photophoresis, in Sezary syndrome, 255
 - with 5-fluorouracil and folinic acid, in metastatic colorectal cancer, 210
 - systemic, hepatic and serologic toxicity, 199
- Interleukin-2
 - with levamisole, in advanced cancer, phase I trial of, 344
 - recombinant, cytogenetic effects of, 50
 - systemic, hepatic and serologic toxicity, 199
- Kaposi's sarcoma, disseminated, in HIV-infected (AIDS) patient, systemic hyperthermia in, 353
- Leucovorin
 - with 5-fluorouracil, in pancreatic cancer, phase II survival study, 467
 - with mitoxantrone and 5-fluorouracil, breast cancer chemotherapy with, 45
 - in sequential methotrexate-5-fluorouracil-leucovorin, with epirubicin, in advanced biliary tract cancer, 223
- Leukemia
 - acute lymphoblastic, adult, CNS relapse in, 93
 - chronic lymphocytic, and hypercalcemia, treated with allogeneic bone marrow transplantation, 360
 - chronic myelogenous, clinical course of, 19
 - and Down syndrome, 452
- Levamisole, with recombinant interleukin-2, in advanced cancer, phase I trial of, 344
- Lipiodol, with cisplatin, chemoembolization, in liver cancer, 405
- Liver, transplanted, radiation tolerance of, 129
- Liver cancer, chemoembolization with cisplatin and lipiodol, phase I study of, 405
- Locoregional therapy, of non-small cell lung cancer, 26
- Lorazepam, enhancement of antiemetic efficacy of dexamethasone with promethazine, 417
- Lung
 - metastases to
 - adamantinoma of bone, 157
 - osteosarcoma, 22
 - superior sulcus tumors, combined treatment of, 317
- Lung cancer
 - non-small cell
 - acivicin in, versus etoposide-cisplatin, 215
 - cisplatin-resistant, pentoxifylline plus nifedipine in, 313
 - etoposide-cisplatin in, 383
 - etoposide in, continuous oral regimen, 163
 - ifosfamide, carboplatin, and etoposide in, phase II study of, 509
 - inoperable, alternating chemotherapy in, 83

- metastatic, chemotherapy in, 239
- neoadjuvant treatment of, 26
 - cisplatin and etoposide in, 64
- small cell
 - chemotherapy of, 160, 527
 - cisplatin-resistant, pentoxifylline plus nifedipine in, 313
- Luteinizing hormone-releasing hormone agonist, in
 - hormonotherapy for prostate cancer, hepatocellular carcinoma during, 390
- Lymphadenectomy, retroperitoneal, in ovarian cancer, 230
- Lymph node, involvement
 - in breast cancer, 461
 - in ovarian cancer, 230
- Lymphocytes, human, cytogenetic effects of interleukin-2 on, 50
- Lymphoma, primary central nervous system, 286
- MACOP-B, in non-Hodgkin's lymphoma, 323
- Mast cell disease, bone pain in, radiotherapy in, 328
- Melanoma
 - metastatic, neuron-specific enolase as tumor marker in, 430
 - stage II, adjuvant chemotherapy for, 55
 - uveal, postirradiation histopathology of, 298
- Mesothelioma, malignant, α -interferon in, 80
- Methotrexate-5-fluorouracil-leucovorin, sequential, with
 - epirubicin, in advanced cancer of extrahepatic biliary system, 223
- Metoclopramide, in cisplatin-induced emesis, 422
- Mitomycin C
 - in anthracycline-pretreated breast cancer, 218
 - in metastatic non-small cell lung cancer, 239
- Mitoxantrone
 - in anthracycline-pretreated breast cancer, 218
 - with 5-fluorouracil and leucovorin, in breast cancer, 45
- Monoclonal antibody, B72.3, 331
- Multidrug resistance, in renal cell carcinoma, 10
- Multiple myeloma, previously treated, carboplatin in, 196
- Musculoskeletal Oncology: A Multidisciplinary Approach* (Lewis MM, ed), reviewed, 181
- National Surgical Adjuvant Breast and Bowel Project, 382
 - study of colony-stimulating factors in high-dose chemotherapy, 374
- Nausea and vomiting. *See* Emesis
- Neoadjuvant chemotherapy
 - in head and neck cancer, 6
 - in non-small cell lung cancer, 26, 64
 - in oral cavity tumors, 1
 - in superior sulcus tumors, 317
- Neuron-specific enolase, as tumor marker in metastatic melanoma, 430
- Neutropenia, with fever, antibiotic therapy in, 400
- Non-Hodgkin's lymphoma, MACOP-B in, 323
- Non-small cell lung cancer. *See* Lung cancer, non-small cell
- Novantrone, 5-fluorouracil, and leucovorin, breast cancer chemotherapy with, 45
- Oncogene amplification, *c-myc*, and prognosis for sarcoma, 273
- ONCOScint[®] CR/OV, prior to second-look surgery, in ovarian cancer, 331
- Ondansetron, antiemetic efficacy of, 137, 147
 - alone
 - versus in combination regimen, trial of, 150
 - versus ondansetron plus alprazolam, 516
 - with dexamethasone, versus standard combination antiemetic therapy, 522
 - two versus three doses, in combination with dexamethasone, 269
- Oral cavity
 - and lip, locally advanced cancer of, palliation, 134
 - tumors, 1
- Osteitis, pelvic, radiation-induced, 248
- Osteoporosis, pelvic radiation-induced, 248
- Osteosarcoma, metastatic, positron emission tomography in, 22
- Ovarian cancer
 - cisplatin-resistant, pentoxifylline plus nifedipine in, 313
 - high-risk early-stage, chemotherapy versus radiation therapy in, 72
 - lymph node involvement in, 230
 - salvage therapy, 490
 - second-line treatment for, 335
 - second-look surgery, immunoscintigraphy using ¹¹¹Cyt103 prior to, 331
- Pain
 - bone, in mast cell disease, radiotherapy in, 328
 - strontium-89 therapy and, with bone metastases, 77
- Palliation
 - for bone pain in mast cell disease, 328
 - of fungating breast cancer, intra-arterial chemotherapy in, 118
 - for locally advanced cancer of oral cavity and lip, 134
- Pancreatic cancer
 - 5-fluorouracil and leucovorin in, phase II survival study, 467
 - single agent chemotherapy in, 166
- Panniculitis, cytophagic histiocytic, modified CHOP-E in, 470
- Pediatric Neuro-oncology: Trends in Clinical Research* (Packer RJ et al, eds), reviewed, 181
- Pelvis, female, radiation osteitis and insufficiency fractures, 248
- Pentoxifylline, with nifedipine, in cisplatin-resistant cancer, 313
- Photophoresis, extracorporeal, and recombinant interferon alfa 2b, in Sezary syndrome, 255
- Piritrexim, in bladder cancer, 448
- Plasmacytoma, extramedullary, cardiac, 427
- Positron emission tomography, in metastatic osteosarcoma, 22
- Procollagen, as bone formation marker, and strontium-89 therapy, 77
- Prostate cancer
 - amonafile in, 514
 - hormonotherapy in, hepatocellular carcinoma during, 390
 - prostate-specific antigen as tumor marker in, 432
 - stage TC, radical prostatectomy and adjuvant therapy in, 277
- Prostatectomy, in stage TC prostate cancer, with adjuvant therapy, 277
- Prostate-specific antigen, as tumor marker, in prostate cancer, 432
- Proton therapy, facility design, 109
- Radiation therapy
 - in adamantinoma metastatic to lung, 157
 - adjuvant, in rectal cancer, 264
 - in advanced (stage IIB-III) cervical cancer, 294
 - angiosarcoma induced by, 444
 - for bone pain in mast cell disease, 328
 - in breast cancer, 348
 - in colorectal cancer metastatic to trachea, 227
 - external beam
 - in brain metastases, 234
 - in brain tumors, 396
 - in Hodgkin's disease, 189
 - intraoperative
 - in brain tumors, 396
 - in superior sulcus tumors, 317
 - in malignant glioma, 437
 - in ovarian cancer, versus chemotherapy, 72
 - pelvic osteitis and fractures induced by, 248
 - postsurgery, in breast cancer, 60
 - in primary lymphoma of central nervous system, 286

in retreatment of regionally recurrent head and neck cancer, 338
in squamous cell head and neck cancer, 369
of transplanted liver, 129

Rectal cancer. *See also* Colorectal cancer
adjunctive radiotherapy in, 264
local excision and postoperative radiation therapy in, 411

Renal cell carcinoma, vinblastine plus dipyrindamole in, 10

Research Fraud in the Behavioral and Biomedical Sciences (Miller DD, Hersen M, eds), reviewed, 182

Retelliptine dihydrochloride, phase I trial of, 242

Sarcoma
prognosis for, with *c-myc* oncogene amplification, 273
soft tissue, ifosfamide and etoposide in, 480

Sezary syndrome, extracorporeal photophoresis and recombinant interferon alfa 2b in, 255

Sister chromatid exchange, 50

Small cell lung cancer. *See* Lung cancer, small cell

Southeastern Cancer Study Group, prognostic factor analysis of CNS relapse in adult acute lymphoblastic leukemia, 93

Southwest Oncology Group, phase II trial of amonafide in endometrial carcinoma, 37
for prostate cancer, 514

Spirogermanium, in pancreatic cancer, 166

Squamous cell carcinoma
of cervix, amonafide in, 125
esophageal, intracavitary brachytherapy in, 170
of head and neck
chemotherapy, granulocyte-macrophage colony-stimulating factor in, 494
concurrent radiation therapy and chemotherapy in, 369

Squamous cell carcinoma antigen, in cervical cancer monitoring, 307

SR 95325 B. *See* Retelliptine dihydrochloride

Steroids, in brain metastases, 234

Stomatitis, 5-fluorouracil-induced, allopurinol mouthwash in, 246

Strontium-89 therapy, in bone metastases, 77

Superior sulcus tumors, combined treatment of, 317

Synchrotron, for proton therapy, 109

Tamoxifen, in breast cancer, 102

Testicular cancer, and Down syndrome, 452

Toxicity
amonaide, 37
carboplatin, in previously treated multiple myeloma, 196
of interferon- α , 199
of interleukin-2, 199
of retelliptine dihydrochloride, 242

Trachea, colorectal cancer metastatic to, 227

Tumor-associated trypsin inhibitor, in cervical cancer monitoring, 307

Tumor lysis syndrome, in nonhematologic malignancy, 502

Ultrasound, esophageal, 14

Uveal tract, melanoma, postirradiation histopathology of, 298

Vinblastine, with dipyrindamole, in renal cell carcinoma, 10

Vincristine, with Adriamycin, procarbazine, and etoposide (VAPE), in small cell lung cancer, 527

Vindesine, with dacarbazine and cisplatin, in stage II melanoma, 55

Vomiting. *See* Emesis

VP-16. *See* Etoposide



Statement of Ownership, Management and Circulation (Required by 39 U.S.C. 3685)

1A. Title of Publication American Journal of Clinical Oncology: Cancer Clinical Trials		1B. PUBLICATION NO. 0 10 3 3 1 5		1C. Date of Filing October 1, 1998
2. Frequency of Issue Semiannually		3A. No. of Issues Published Annually 6		3B. Annual Subscription Price \$198 US / \$238 Foreign
4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Do not print)				
1185 Avenue of the Americas, New York, New York 10036				
5. Complete Mailing Address of the Headquarters or General Business Office of the Publisher (Do not print)				
1185 Avenue of the Americas, New York, New York 10036				
6. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not print if the Publisher is the Editor and Managing Editor)				
Raven Press, 1185 Avenue of the Americas, New York, New York 10036				
Editor (Name and Complete Mailing Address) Dr. Luther N. Brady, Department of Radiation Oncology and Nuclear Medicine, Jefferson University, Broad and Vine Streets, Rm 250, Philadelphia, Pennsylvania 19102				
Managing Editor (Name and Complete Mailing Address) Antoinette Cincio, Raven Press, 1185 Avenue of the Americas, New York, New York 10036				
7. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a corporation or other entity, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. Do not print if the Publisher is the Editor and Managing Editor)				
Full Name		Complete Mailing Address		
Raven Press Ltd		1185 Avenue of the Americas, N.Y., N.Y. 10036		
Wolters Kluwer US		New York, N.Y.		
Wolters Kluwer (US) Inc.		New York, N.Y.		
8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities. If none, so state.				
Full Name		Complete Mailing Address		
NONE				
9. For Completion by Nonprofit Organizations Authorized to Mail at Nonprofit Rates (Section 501(c)(3) only). The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)				
(1) Has Not Changed During Preceding 12 Months				
(2) Has Changed During Preceding 12 Months				
10. If changed, publisher must submit explanation of change and the amount				
Report and Nature of Circulation (Do not print if the Publisher is the Editor and Managing Editor)		Average No. Copies Each Issue During Preceding 12 Months		Actual No. Copies of Single Issue Published Nearest to Filing Date
A. Total No. Copies (Net Press Run)		2390		2128
B. Paid and/or Requested Circulation				
1. Sales through dealers and carriers, street vendors and counter sales		1419		1445
2. Mail Subscriptions (Other orders reported)		1419		1445
C. Total Paid and/or Requested Circulation (Sum of 10B1 and 10B2)		1419		1445
D. Free Distribution by Mail: Carriers or Other Means (Samples, Complimentary, and Other Free Copies)		149		149
E. Total Distribution (Sum of C and D)		1568		1594
F. Copies Not Distributed		782		534
1. Office use, left-hand, unaccounted, spoiled after printing				
2. Return from News Agents				
G. TOTAL (Sum of E, F1 and F2—should equal net press run shown in 10A)		2390		2128
11. I certify that the statements made by me above are correct and complete				
Signature of Publisher, Editor, or Business Manager (Do not print)		(212) 930-9025		

PS Form 3526, January 1991

Other information on reverse

